Trialect

+ More Filters

Reset Filters

Specialty

Funding Organization

Funding Type

Eligible Country

Deadline

From

Other (Select all that apply)

Show Expired Programs

Show Verified Programs

Verified

CRI Lloyd J. Old STAR Program

Cancer Research Institute

Named for CRI’s founding scientific and medical director, whose vision and expertise guided CRI’s programs for forty years, earning him the title “Father of Modern Tumor Immunology,” the CRI Lloyd J. Old STAR Program supports today’s scientific visionaries.

Candidates selected for this award are expected to be the future leaders in the field of cancer immunotherapy, and this sustained funding will enable them to carry out transformational research. Because the funds are not restricted to a particular project, the award allows the recipients to follow new and promising lines of investigation, which often lead to unanticipated scientific breakthroughs. This long-term funding provides a degree of flexibility and freedom to explore outside-the-box and disruptive avenues of research.

The profile of a recipient investigator would be a scientist who takes risks with the expectation of high rewards, even in the face of potential failure. They will use their expertise, scientific acumen, and visionary curiosity to ask important, significant, and often non-obvious immunological questions. They will be the rare researcher who connects disparate pieces of discoveries, often from multiple disciplines, to develop and test new hypotheses that lead to step changes in our understanding and innovation to the field of cancer immunotherapy.

It is expected that their discoveries in basic or translational research will ultimately influence the development of new immune-based therapies that will be effective for more cancer patients. CRI Lloyd J. Old STARs will be at the forefront of discovery and innovation and will be viewed as the leaders in scientific thought and invention.

Specialties

Cancer

Oncology

Immunology

Eligibility Requirements

Candidates for the Lloyd J. Old STAR program must meet the following eligibility requirements:

The applicant must have an M.D., Ph.D., or M.D./Ph.D. (or equivalent)
Applicants must belong to one of the following categories as of July 1 (following the deadline):
- Tenure-track assistant professor with a minimum of 3 years in this position (for Jan. 15, 2025, deadline must be appointed on or before July 1, 2022)
- Tenure-track associate professor with a maximum of 3 years in this position (for Jan. 15, 2025, deadline must be appointed on or after July 1, 2022)

Adjunct or acting positions are not eligible.

Applicants are expected to commit a minimum of 80% of their time to conducting research.

CRI has no citizenship restrictions, and research supported by the award may be conducted at medical schools and research centers in the United States or abroad. Please note that the Cancer Research Institute does not support research at for-profit institutions.

Sponsor Details

Sponsor Institute/Organizations: Cancer Research Institute

Address: Cancer Research Institute 29 Broadway, Floor 4 New York, NY 10006-3111

Legal & Affiliation Disclaimer

Affiliation Disclaimer: Trialect operates independently and is not affiliated with, endorsed by, or supported by any sponsors or organizations posting on the GrantsBoard platform. As an independent aggregator of publicly available funding opportunities, Trialect provides equal access to information for all users without endorsing any specific funding source, content, organization, or sponsor. Trialect assumes no responsibility for the content posted by sponsors or third parties.

Subscription Disclaimer: Upon logging into Trialect, you may choose to SUBSCRIBE to GrantsBoard for timely notifications of funding opportunities and to access exclusive benefits, such as priority alerts, reminders, personalized recommendations, and additional application support. However, users are advised to contact sponsors directly for any questions and are not required to subscribe to engage with funding opportunities.

Content Ownership and Copyright Disclaimer: Trialect respects the intellectual property rights of all organizations and individuals. All content posted on GrantsBoard is provided solely for informational purposes and remains the property of the original owners. Trialect does not claim ownership of, nor does it have any proprietary interest in, content provided by third-party sponsors. Users are encouraged to verify content and ownership directly with the posting sponsor.

Fair Use Disclaimer: The information and content available on GrantsBoard are compiled from publicly accessible sources in alignment with fair use principles under U.S. copyright law. Trialect serves as an aggregator of this content, offering it to users in good faith and with the understanding that it is available for public dissemination. Any organization or individual who believes their intellectual property rights have been violated is encouraged to contact us for prompt resolution.

Third-Party Posting Responsibility Disclaimer: Trialect is a neutral platform that allows third-party sponsors to post funding opportunities for informational purposes only. Sponsors are solely responsible for ensuring that their postings comply with copyright, trademark, and other intellectual property laws. Trialect assumes no liability for any copyright or intellectual property infringements in third-party content and will take appropriate action to address any substantiated claims.

Accuracy and Verification Disclaimer: Trialect makes no warranties regarding the accuracy, completeness, or reliability of the information provided by sponsors. Users are advised to verify the details of any funding opportunity directly with the sponsor before taking action. Trialect cannot be held liable for any discrepancies, omissions, or inaccuracies in third-party postings.

Notice and Takedown Policy: Trialect is committed to upholding copyright law and protecting the rights of intellectual property owners. If you believe that content on GrantsBoard infringes your copyright or intellectual property rights, please contact us with detailed information about the claim. Upon receipt of a valid notice, Trialect will promptly investigate and, where appropriate, remove or disable access to the infringing content.

View Funding Opportunity

Grant

Final Deadline:

Jan 15, 2025

Funding Amount:

$1,250,000

Questions and Answers

Commonly asked questions about this funding opportunity from the host and other attendees.

1. My institution does not use the titles of assistant professor nor associate professor, can I still apply?

• If the institution from which you are applying considers your current academic rank the equivalent of an assistant professor or associate professor, you are still eligible to apply.

2. Can a STAR grant be awarded to a candidate at a foreign institution?

• Yes, candidates from both U.S. and non-U.S. institutions are eligible to apply, provided that the institution is a non-profit entity.

3. Does CRI have a citizenship restriction for its grant programs?

• There are no citizenship restrictions for any of CRI’s grant programs.

4. Does CRI provide feedback on unfunded proposals?

• No, CRI does provide applicants of unfunded proposals comments or feedback from our reviewers.

5. What is CRI’s resubmission policy?

• CRI allows applicants to resubmit an unfunded application for subsequent deadlines following the completion of CRI’s review process. However, CRI does not provide feedback or reviewer comments on applications. New applications should, however, reflect any progress made since the previous submission, with changes to the application highlighted.

6. Is there a limitation of the number of times I can apply for this grant program?

• No, so long as you meet the eligibility requirements you may still apply.

7. Can more than one applicant from the same institution apply for funding?

• Yes, multiple applicants from the same organization may submit proposals to each CRI funding announcement, provided each application is scientifically distinct.

8. Is an IRB/IACUC/IBC approval required at the time of submitting my application?

• No, however, applicants should list on the application “pending” if the protocol has not yet been approved. For applications that involve human subjects, vertebrate animals, recombinant DNA and other nonexempt biohazards, an applicable protocol number would need to be required following the acceptance of the award.